Approach to Hypertrophic Cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Internal Medicine

Background:

• Hypertrophic cardiomyopathy (HCM) is a genetic disorder causing left ventricular (LV) hypertrophy.
• Approximately 20% of patients experience dynamic LV outflow obstruction.
• Clinical presentations range from asymptomatic to sudden cardiac death, heart failure, or atrial fibrillation (AF).

Purpose of the Study:

• To outline the risk stratification for sudden cardiac death in HCM.
• To discuss management strategies for heart failure symptoms, LV outflow obstruction, and AF in HCM patients.

Main Methods:

• Risk stratification for sudden death involves markers like prior cardiac arrest, family history, extreme LV hypertrophy, syncope, and arrhythmias.
• Heart failure management focuses on diastolic dysfunction with beta-blockers or verapamil.
• LV outflow obstruction unresponsive to medication is treated with myectomy or alcohol septal ablation.

Main Results:

• Implantable cardioverter-defibrillators are recommended for patients with significant risk factors for sudden death.
• Beta blockers or verapamil manage heart failure symptoms and AF rate control.
• A low threshold for anticoagulation is advised due to high embolization risk in AF patients.

Conclusions:

• Effective management of HCM involves risk stratification for sudden death and tailored therapies for heart failure, outflow obstruction, and AF.
• Early intervention with devices or procedures can improve outcomes and quality of life.